Résumé
BACKGROUND: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor, approved for treatment of moderate to severe active RA in Europe, the UK, and Japan. Graded laboratory abnormalities from placebo-controlled analyses and long-term data on lymphocytes have been reported previously. OBJECTIVES: Report the effect of FIL on laboratory parameters in the FINCH 4 long-term extension (LTE). […]